载氯倍他索可生物降解纳米粒作为牙髓腔内药物的研发
本研究开发并优化了负载抗炎药氯倍他索丙酸酯(CP)的PLGA可生物降解聚合物纳米粒(CP-NPs),拟用作牙髓腔内药物,针对体外暴露时间过长的撕脱牙。CP-NPs平均粒径小于200 nm、呈单峰分布、球形且不聚集,48 h仅释放21%的CP,能增强对牙本质小管的渗透,并可显著降低TNF-α释放。
要点
- CP-NPs粒径小于200 nm,48 h仅释放21%的CP,具有缓释特性。
- CP-NPs对牙本质小管的渗透优于游离CP。
- CP-NPs可显著降低TNF-α释放,对撕脱牙有潜在治疗价值。
核心结论
- CP-NPs对牙本质小管的渗透程度较游离CP显著增加,并能显著降低TNF-α释放。
- CP-NPs因此有望用于治疗体外暴露时间过长的撕脱牙。
研究设计与样本
- 采用溶剂置换法制备负载CP的PLGA纳米粒(CP-NPs)。
- 评估CP-NPs在48 h内的CP释放曲线,并与游离CP对照。
- 使用离体人牙研究CP-NPs与CP对牙本质小管的渗透程度。
- 体外评估CP-NPs对炎症细胞(尤其巨噬细胞)的抗炎能力。
- 采用ELISA检测IL-1β和TNF-α的释放。
主要发现
- 优化后的CP-NPs平均粒径小于200 nm,呈单峰分布。
- 透射电镜证实CP-NPs为球形且不聚集。
- 相互作用研究显示CP被包裹在纳米粒内部,未形成共价键。
- CP-NPs释放缓慢而稳定,48 h后仅释放21%的包裹CP。
- 共聚焦激光扫描显微镜观察到CP-NPs对牙本质小管的渗透增强。
关键数值与推荐
- CP-NPs在48 h内仅释放21%的包裹CP。
- CP-NPs组TNF-α和IL-1β释放较LPS对照未增加,48 h结果与TCP相似甚至更低。
- LPS刺激细胞中,巨噬细胞经CP-NPs处理后IL-1β释放降低。
临床怎么用
- CP-NPs可作为撕脱牙体外暴露时间过长时牙髓腔内药物的候选方案。
- 其缓释与增强的牙本质小管渗透特性有利于局部抗炎作用。
局限性
- 研究为体外实验,尚需进一步体内验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The aim of current study is the development and optimization of biodegradable polymeric nanoparticles (NPs) to be used in the field of Endodontics as intracanal medication in cases of avulsed teeth with extended extra-oral time, utilizing PLGA polymers loaded with the anti-inflammatory drug clobetasol propionate (CP). METHODOLOGY: CP-loaded nanoparticles (CP-NPs) were prepared using the solvent displacement method. CP release profile from CP-NPs was assessed for 48 h against free CP. Using extracted human teeth, the degree of infiltration inside the dentinal tubules was studied for both CP-NPs and CP. The anti-inflammatory capacity of CP-NPs was evaluated in vitro measuring their response and reaction against inflammatory cells, in particular against macrophages. The enzyme-linked immunosorbent assay (ELISA) was used to examine the cytokine release of IL-1β and TNF-α. RESULTS: Optimized CP-NPs displayed an average size below 200 nm and a monomodal population. Additionally, spherical morphology and non-aggregation of CP-NPs were confirmed by transmission electron microscopy. Interaction studies showed that CP was encapsulated inside the NPs and no covalent bonds were formed. Moreover, CP-NPs exhibited a prolonged and steady release with only 21% of the encapsulated CP released after 48 h. Using confocal laser scanning microscopy, it was observed that CP-NPs were able to display enhanced penetration into the dentinal tubules. Neither the release of TNF-α nor IL-1β increased in CP-NPs compared to the LPS control, displaying results similar and even less than the TCP after 48 h. Moreover, IL-1β release in LPS-stimulated cells, decreased when macrophages were treated with CP-NPs. CONCLUSIONS: In the present work, CP-NPs were prepared, optimized and characterized displaying significant increase in the degree of infiltration inside the dentinal tubules against CP and were able to significantly reduce TNF-α release. Therefore, CP-NPs constitute a promising therapy for the treatment of avulsed teeth with extended extra-oral time.
引用
- Elmsmari F, González Sánchez JA, Delgado LM, et al. Development of clobetasol-loaded biodegradable nanoparticles as an endodontic intracanal medicament. Int Endod J. 2024. PMID: 38687284. doi:10.1111/iej.14072
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。